Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidziński M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjørge L, Lortholary A, Sailer MO, Merger M, Harter P; AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium.

Lancet Oncol. 2016 Jan;17(1):78-89. doi: 10.1016/S1470-2045(15)00366-6. Epub 2015 Nov 16.

PMID:
26590673
2.

Effectiveness of a novel biodegradable polymer, sirolimus-eluting stent platform in percutaneous coronary intervention.

Dominici M, Arrivi A, Bazzucchi M, De Paolis M, Milici C, Bock C, Placanica A, Lazzari L, Diletti R, Boschetti E.

Minerva Cardioangiol. 2016 Feb;64(1):1-8. Epub 2015 Oct 7.

PMID:
26446510
3.

Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.

Márquez-Rodas I, Martín González M, Nagore E, Gómez-Fernández C, Avilés-Izquierdo JA, Maldonado-Seral C, Soriano V, Majem-Tarruella M, Palomar V, Maseda R, Martín-Carnicero A, Puertolas T, Godoy E, Cerezuela P, Ochoa de Olza M, Campos B, Perez-Ruiz E, Soria A, Gil-Arnaiz I, Gonzalez-Cao M, Galvez E, Arance A, Belon J, de la Cruz-Merino L, Martín-Algarra S; Spanish Multidisciplinary Group of Melanoma (GEM).

PLoS One. 2015 Apr 13;10(4):e0124239. doi: 10.1371/journal.pone.0124239. eCollection 2015.

4.

Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.

Sotelo MJ, Sastre J, Maestro ML, Veganzones S, Viéitez JM, Alonso V, Grávalos C, Escudero P, Vera R, Aranda E, García-Alfonso P, Gallego-Plazas J, Lopez C, Pericay C, Arrivi A, Vicente P, Ballesteros P, Elez E, López-Ladrón A, Díaz-Rubio E.

Ann Oncol. 2015 Mar;26(3):535-41. doi: 10.1093/annonc/mdu568. Epub 2014 Dec 15.

5.

Aspirin reload before elective percutaneous coronary intervention: impact on serum thromboxane b2 and myocardial reperfusion indexes.

Basili S, Tanzilli G, Raparelli V, Calvieri C, Pignatelli P, Carnevale R, Dominici M, Placanica A, Arrivi A, Farcomeni A, Barillà F, Mangieri E, Violi F.

Circ Cardiovasc Interv. 2014 Aug;7(4):577-84. doi: 10.1161/CIRCINTERVENTIONS.113.001197. Epub 2014 Jul 29.

6.

Spontaneous-idiopathic left anterior descending artery dissection: is watchful waiting better than immediate stenting?

Arrivi A, Bazzucchi M, De Paolis M, Placanica A, Bock C, Milici C, Boschetti E, Dominici M.

Case Rep Vasc Med. 2013;2013:639384. doi: 10.1155/2013/639384. Epub 2013 Sep 10.

7.

Rosuvastatin was Effective in Acute Heart Failure and Slow Coronary Flow: A Hypothesis-generating Case Report.

Arrivi A, Tanzilli G, Puddu PE, Iannucci L, Mangieri E.

Open Cardiovasc Med J. 2013;7:12-5. doi: 10.2174/1874192401307010012. Epub 2013 Jan 31.

8.

Operator exposure to x-ray in left and right radial access during percutaneous coronary procedures: OPERA randomised study.

Dominici M, Diletti R, Milici C, Bock C, Placanica A, D'Alessandro G, Arrivi A, Italiani M, Buono E, Boschetti E.

Heart. 2013 Apr;99(7):480-4. doi: 10.1136/heartjnl-2012-302895. Epub 2013 Jan 23.

PMID:
23343690
9.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group.

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

10.

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Reboredo M, Manzano JL, Rivera F, Safont MJ, Montagut C, González E, Benavides M, Marcuello E, Cervantes A, Martínez de Prado P, Fernández-Martos C, Arrivi A, Bando I, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

PLoS One. 2012;7(10):e47345. doi: 10.1371/journal.pone.0047345. Epub 2012 Oct 12.

11.

Idiopathic, serial coronary vessels dissection in a young woman with psychological stress: a case report and review of the literature.

Arrivi A, Milici C, Bock C, Placanica A, Boschetti E, Dominici M.

Case Rep Vasc Med. 2012;2012:498465. doi: 10.1155/2012/498465. Epub 2012 Oct 23.

12.

Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.

Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E.

Oncologist. 2012;17(7):947-55. doi: 10.1634/theoncologist.2012-0048. Epub 2012 May 29.

13.

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.

Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors.

Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10.

14.

Acute Aortic Dissection Mimicking STEMI in the Catheterization Laboratory: Early Recognition Is Mandatory.

Arrivi A, Tanzilli G, Puddu PE, Truscelli G, Dominici M, Mangieri E.

Case Rep Cardiol. 2012;2012:367542. doi: 10.1155/2012/367542. Epub 2012 Sep 27.

15.

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).

Aranda E, Manzano JL, Rivera F, Galán M, Valladares-Ayerbes M, Pericay C, Safont MJ, Mendez MJ, Irigoyen A, Arrivi A, Sastre J, Díaz-Rubio E.

Ann Oncol. 2012 Jul;23(7):1919-25. doi: 10.1093/annonc/mdr560. Epub 2011 Dec 9.

16.

Recommendations and expert opinion on the treatment of locally advanced rectal cancer in Spain.

Grávalos C, García-Alfonso P, Afonso R, Arrazubi V, Arrivi A, Cámara JC, Capdevila J, Gómez-España A, Lacasta A, Manzano JL, Salgado M, Sastre J, Díaz-Rubio E.

Clin Transl Oncol. 2011 Dec;13(12):862-8. doi: 10.1007/s12094-011-0747-1. Review.

PMID:
22126729
17.

Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.

Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C; AVACROSS Study Group.

Oncologist. 2011;16(5):614-20. doi: 10.1634/theoncologist.2010-0285. Epub 2011 Apr 5.

18.

Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study.

Morales R, Cuadrado A, Noguera JF, Dolz C, Vilella A, Riera J, González de Cabo M, Arriví A, Falcó E, García Bonafe M, Company M, Vicens JC, Socías A.

Rev Esp Enferm Dig. 2011 Jan;103(1):5-12.

19.

320-slice CT and myocardial bridge.

Evangelista A, Pelliccia F, Arrivi A, Gaudio C.

BMJ Case Rep. 2011 Jun 17;2011. pii: bcr0520114200. doi: 10.1136/bcr.05.2011.4200. No abstract available.

20.

Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of true coronary bifurcations: the PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE bifuRcations) study.

Tanzilli G, Pelliccia F, Pasceri V, Speciale G, Greco C, Arrivi A, Viceconte N, Mangieri E, Gaudio C.

Int J Cardiol. 2011 Jan 21;146(2):240-1. doi: 10.1016/j.ijcard.2010.10.052. Epub 2010 Nov 19. No abstract available.

PMID:
21093942
Items per page

Supplemental Content

Loading ...
Write to the Help Desk